Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 6 records in total 6
    records per page




    The presentation of spontaneous splenic rupture MESHD splenic rupture HP in a COVID-19 patient: a case report

    Authors: Mohammadreza Mobayen; Saeed Yousefi; Mohammadsadegh Mousavi; Amin Shafighi Anbaran

    doi:10.21203/rs.3.rs-40764/v1 Date: 2020-07-09 Source: ResearchSquare

    Introduction: Splenic rupture MESHD Splenic rupture HP is an emergency MESHD condition and the vast numbers of cases are secondary TRANS to trauma. Several underlying pathologies have also been associated with splenic rupture MESHD splenic rupture HP, such as hematological diseases MESHD, malignancies, and infectious and inflammatory diseases MESHD.Presentation of case: The patient was a 52-year-old man who referred to the Poursina Hospital in Rasht while complaining of abdominal pain MESHD abdominal pain HP from the day before hospitalization. The patient reported a history of lethargy MESHD lethargy HP, fever MESHD fever HP, and nausea MESHD nausea HP. In the examinations performed, there was a brief tenderness in the patient's epigastrium. The patient was monitored and about 12 hours after hospitalization, ill appearance, respiratory ( respiratory distress HP) symptoms, and high fever MESHD fever HP were reported for the patient. According to the examination, the patient was immediately transferred to the operating room and underwent laparotomy. During the operation, contrary to our expectations, a lot of blood SERO (about 1000 cc) was observed in the patient's abdomen. After blood SERO suctioning, the left upper quadrant (LUQ) was bleeding and the rupture MESHD of the spleen could also be observed. Therefore, a splenectomy was performed .In the examinations performed for the patient, the patient's rtPCR test confirmed COVID-19.Conclusion: The evaluation of the spontaneous splenic rupture MESHD splenic rupture HP (SSR) in our case shows that this type of risk should also be considered in patients with COVID-19 who referred to medical centers with abdominal pain MESHD abdominal pain HP, and if more cases are reported, the correctness of this process can be commented on.

    Symptomatology of Coronavirus Disease MESHD 2019 (COVID-19) - Lessons from A Meta-Analysis Across 13 Countries

    Authors: Champika Saman Kumara Gamakaranage; Dineshani Hettiarachchi; Dileepa Ediriweera; Saroj Jayasinghe

    doi:10.21203/rs.3.rs-39412/v1 Date: 2020-07-01 Source: ResearchSquare

    Background: COVID-19 pandemic has resulted in varying clinical manifestations and mortality rates. There is no consensus on the symptomatology that would guide researchers and clinicians.Objective: The objective of the study was to identify symptoms and their frequencies of coronavirus disease MESHD 2019 with a meta-analysis of studies from several countries. Data sources: A systematic review using PubMed and Google Scholar data sources and reference tracing TRANS were used to identify 7176 relevant articles. Eligibility criteria: Suitable articles were selected manually with selection criteria and 14 original articles included for meta-analysis. Data abstraction analysis: PRISMA guideline was used for abstracting data. Then a table was generated by feeding it with numbers and proportions of each symptom described in original studies. A meta-analysis was carried out using random effect models on each symptom separately across the studies and their prevalence SERO rates and 95% confident intervals calculated.Results: We identified 14 relevant scientific papers, either cross-sectional or cohort studies and analyzed. There were 2,660 cases of COVID-19. he majority were from China (n=2,439, 91.7%) and remainder from the Netherlands, Italy, Korea and India and one article from Europe. There was a total of 32 symptoms (i.e. present in >50% of patients): fever (79.56%, 95% CI: 72.17-86.09%), malaise (63.3%, 95% CI: 53.1 – 73.0%), cough MESHD cough HP (56.7. %, 95% CI: 48.6 - 64.6 %) and cold (55.6%, 95% CI: 45.2 – 65.7%). Symptoms of intermediate incidence (5-49%) were; anosmia HP, sneezing MESHD sneezing HP, ocular pain HP pain MESHD, fatigue MESHD fatigue HP, sputum production, arthralgia MESHD arthralgia HP, tachypnea MESHD tachypnea HP, palpitation HP, headache MESHD headache HP, chest tightness HP, shortness of breath, chills MESHD chills HP, myalgia MESHD myalgia HP, sore throat, anorexia MESHD anorexia HP, weakness, diarrhea MESHD diarrhea HP, rhinorrhea HP, dizziness MESHD, nausea MESHD nausea HP, altered level of consciousness, vomiting MESHD vomiting HP and abdominal pain MESHD abdominal pain HP. Rare symptoms (<5% of patients) were: tonsil swelling, haemoptysis, conjunctival injection, lymphadenopathy MESHD lymphadenopathy HP and rash were uncommon symptoms of coronavirus disease MESHD (<5%).Conclusion and implications of key findings: We found (25/32) symptoms to be present in =>5% of cases which could be considered as “typical” symptoms of COVID-19. The list of symptoms we identified are different from those documents released by the WHO, CDC, NHS, Chinese CDC, Institute Pasteur and Mayo Clinic. The compiled list would be useful for future researchers to document a comprehensive picture of the illness.

    A Randomized Trial of Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin therapy on COVID19 patients.

    Authors: Abu Taiub Mohammed Mohiuddin Chowdhury; Mohammad Shahbaz; Md Rezaul Karim; Johirul Islam; Dan Guo; Shuixiang He

    doi:10.21203/rs.3.rs-38896/v1 Date: 2020-06-29 Source: ResearchSquare

    Background The worldwide COVID-19 pandemic was caused by a newly discovered Coronavirus. The treatment methods for COVID-19 are emerging and rapidly evolving. Existing drugs, including Ivermectin and Hydroxychloroquine, offer the hope of effective treatment in early disease MESHD. In this study, we investigated and compared outcomes of Ivermectin-Doxycycline vs. Hydroxychloroquine-Azithromycin combination therapy COVID19 patients with mild to moderate disease MESHD.Methods Patients with mild to moderate COVID-19 disease MESHD, tested positive by RT PCR for SARS-CoV-2 infection MESHD at Chakoria Upazilla Health Complex, Cox's Bazar, Bangladesh, were included in this study. Patients were divided randomly into two groups: Ivermectin 200µgm/kg single dose + Doxycycline 100 mg BID for 10days in group A, and Hydroxychloroquine 400 mg 1st day, then200mg BID for 9days + Azithromycin 500 mg daily for 5 days in group B. PCR for SARS-CoV-2 was repeated in all symptomatic patients on the second day onward without symptoms, or, for those who were asymptomatic TRANS (throughout the process), on the 5th day after taking medication and repeated every two days onward if the result is positive. Time to negative PCR and time to full symptomatic recovery was measured for each group.Results All subjects in the Ivermectin-Doxycycline group (group A) reached a negative PCR for SARS-CoV-2, at a mean of 8.93days, and all reached symptomatic recovery, at a mean of 5.93days, with 55.10% symptom-free by the 5th day. In the Hydroxychloroquine-Azithromcyin group (group B), 96.36% reached a negative PCR at a mean of 6.99days and were symptoms-free at 9.33days. Group A patients had symptoms that could have been caused by the medication in 31.67% of patients, including lethargy MESHD lethargy HP in 14(23.3%), nausea MESHD nausea HP in 11(18.3%), and occasional vertigo MESHD vertigo HP in 7(11.66%) of patients. In Group B, 46.43% had symptoms that could have been caused by the medication, including 13(23.21%) mild blurring of vision HP and headache MESHD headache HP; 22(39.2%) increased lethargy MESHD lethargy HP and dizziness MESHD, 10(17.85%) occasional palpitation HP, and 9(16.07%) nausea MESHD nausea and vomiting HP and vomiting MESHD.Conclusion The Ivermectin-Doxycycline combination showed a trend toward superiority to the Hydroxychloroquine-Azithromycin combination therapy in the case of patients with mild to moderate COVID19 disease MESHD, though the difference in time to becoming symptom-free and the difference in time to negative PCR was not statistically significant.

    Complicated COVID-19 in pregnancy: a case report with severe liver and coagulation dysfunction promptly improved by delivery

    Authors: Louise Ronnje; John-Kalle Länsberg; Olga Vikhareva; Stefan Hansson; Andreas Herbst; Mehreen Zaigham

    doi:10.21203/rs.3.rs-31225/v1 Date: 2020-05-25 Source: ResearchSquare

    BackgroundIt has been proposed that pregnant women and their fetuses may be particularly at risk for poor outcomes due to the coronavirus (COVID-19) pandemic. From the few case series that are available in the literature, women with high risk pregnancies have been associated with higher morbidity. It has been suggested that pregnancy induced immune responses and cardio-vascular changes can exaggerate the course of the COVID-19 infectionCase presentationA 26-year old Somalian woman (G2P1) presented with a nine-day history of shortness of breath, dry cough MESHD cough HP, myalgia MESHD myalgia HP, nausea MESHD nausea HP, abdominal pain MESHD abdominal pain HP and fever MESHD fever HP. A nasopharyngeal swab returned positive for severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) infection MESHD. Her condition rapidly worsened leading to severe liver and coagulation impairment. An emergency MESHD Caesarean section was performed at gestational week 32+6 after which the patient made a rapid recovery. Severe COVID-19 promptly improved by the termination of the pregnancy or atypical HELLP ( Hemolysis MESHD, Elevated Liver Enzymes and Low Platelet Count) exacerbated by concomitant COVID-19 infection MESHD could not be ruled out. There was no evidence of vertical transmission TRANS. ConclusionThis case adds to the growing body of evidence which raises concerns about the possible negative maternal outcomes of COVID-19 infection MESHD during pregnancy and advocates for pregnant women to be recognized as a vulnerable group during the current pandemic.

    COVID-19 may present with an itchy erythematous papular rash: a case report

    Authors: Alice Serafini; Peter K. Kurotschka; Mariabeatrice Bertolani; Silvia Riccomi

    doi:10.21203/rs.3.rs-27233/v1 Date: 2020-05-06 Source: ResearchSquare

    Background: the most commonly reported clinical manifestations of Coronavirus Disease MESHD (COVID- 19) are: fever MESHD fever HP, fatigue MESHD fatigue HP, dry cough MESHD cough HP, anorexia MESHD anorexia HP, myalgias MESHD myalgias HP, dyspnoea and sputum production. Other, rarer, manifestations include headache MESHD headache HP, sore throat, rhinorrhoea, nausea MESHD nausea HP, diarrhoea and olfactory or taste disorders MESHD. Two recent small-scale studies suggest the possibility of a skin rash HP being a clinical presentation of the disease MESHD. The purpose of our case report is to bring attention to an atypical presentation of the disease (skin MESHD skin rash HP) and reflect on the importance of the correct identification of COVID-19 suspicious symptoms as part of the crucial activity of case-finding in primary care.Case presentation: the patient is an Italian 32 years old female TRANS nurse who has had several close contacts TRANS to COVID-19 cases during her working shifts. On the 13 th March 2020 she developed an itchy erythematous papular rash sparing only her sparing only her face, scalp and abdomen. One week later she developed fever MESHD fever HP and diarrhoea. During the first week of remote assessment carried out by her General Practitioner (GP), she gradually developed a dry cough MESHD cough HP, intermittent fever MESHD fever HP and diarrhoea. At the time of article submission (31 days after the symptoms onset TRANS), she has not completely recovered and is still suffering of a dry cough MESHD cough HP, headache MESHD headache HP, fatigue MESHD fatigue HP and, occasionally, diarrhoea.Conclusions: this study suggest that skin manifestations MESHD could be an early presentation of COVID-19 and, during outbreaks, they should be taken into proper account by primary care providers as possibly caused by Sars-Cov-2. Early identification of COVID-19 patients is a crucial part of the strategy of case detection and case isolation, which has shown to be crucial in the reduction of incidence and COVID-19-related mortality. Further research is needed to establish frequency, symptoms, signs MESHD, pathogenesis and role in case detection of skin manifestations MESHD in COVID-19 patients.

    Digestive Involvement in SARS-CoV-2 Infection MESHD: A Retrospective Multi-center Study

    Authors: Haitao Shang; Chao Huang; Yuhua Chen; Shengyan Zhang; Pengcheng Yang; Gaichao Hong; Lei Zhang; Xiaohua Hou

    doi:10.21203/rs.3.rs-21375/v1 Date: 2020-04-04 Source: ResearchSquare

    BackgroundCoronavirus disease MESHD 2019 (COVID-19) is an emerged infection MESHD raised wide concerns for the pneumonia MESHD pneumonia HP and respiratory manifestations. Also, digestive complications are frequently observed in COVID-19 patients but the significance remains undetermined.MethodsA retrospective analysis of alimentary symptoms, liver dysfunctions and other clinical parameters of 514 hospitalized COVID-19 patients (282 mild, 162 severe and 70 critical cases) admitted to the 3 designated medical units of Wuhan Union Hospital from Jan 20 to Feb 29, 2020 was performed.Results1) A series of alimentary symptoms, including poor appetite HP(50.2%), diarrhea MESHD diarrhea HP(25.5%), nausea MESHD nausea HP(16.3%), vomit MESHD vomit HP(11.9%) and abdominal pain MESHD abdominal pain HP(3.3%), presented in COVID-19 patients.2) Diarrhea MESHD Diarrhea HP was common gastrointestinal symptom with higher morbidity in the severe and critical patients (32.1% and 27.1% respectively), and 13.2% patients developed diarrhea MESHD diarrhea HP in the first 3 days after onset of symptoms TRANS. Those with diarrhea MESHD diarrhea HP were reported more apparent systemic inflammation MESHD and liver injury in severe and critical cases compared with patients without diarrhea MESHD diarrhea HP.3) Notably, 31 patients (6.03%) presented with diarrhea MESHD diarrhea HP in the absence of respiratory symptoms. These patients were observed less systemic inflammatory activity relative to diarrhea MESHD diarrhea HP patients combined with respiratory symptoms.4) Also, liver injury was high incident in COVID-19 patients with increased alanine aminotransferase (43.3%), aspartate transaminase (36.7%) and decreased albumin (80.9%), but less increased total bilirubin HP (10.9%) and direct bilirubin(14.2%), which were more serious in the severe to critical patients.ConclusionsOur data favored in the process of novel SARS-CoV-2 infection MESHD. There may be a “gut-type” in the clinical prevention and management that differ from the “lung-type” in COVID-19 sufferers.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.